MELBOURNE, Australia and PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/ OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference and participate in one-on-one investor meetings on August 15, 2024.
Virtual Conference Details:
Presentation: Available on Thursday, August 15, 2024, 7:00 am ET
Presenter: Frederic Guerard, PharmD, CEO Opthea
The webcast will be accessible both via the link: https://journey.ct.events/view/bc8c5e95-651e-4824-bee8-923a1a7479fa and on the “Events & Presentations” section of Opthea’s website at http://ir.opthea.com/.
About Opthea
Opthea (ASX/OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, CEO
Investor Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email: [email protected]
Phone: 617-430-7579
Media Inquiries
Silvana Guerci-Lena
NorthStream Global Partners
Email: [email protected]
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: [email protected] Web: www.opthea.com
Source: Opthea Limited
